News & articles

July 15, 2013 Emmanuelle Passegue (University of California, San Francisco) has recently published results of a study of the bone marrow niche. Her focus has been on the osteoblastic lineage cell derivatives. In this study they show that leukemic myeloid cells stimulate stromal cells, causing them to overproduce functionally altered osteoblastic cells, which then accumulate in… Read More »EMMANUELLE PASSEGUE PUBLISHES ON MF STUDY

May 2011 Beginning in 2010 the MPN Research Foundation began playing host to a gathering of MPN specialists in the Chicago area, recruiting doctors from RUSH, Northwestern, University of Chicago, University of Illinois at Chicago, and Loyola. This group, known now as the Chicago MPN Roundtable™, was conceptualized as a way to draw clinicians and… Read More »ANNOUNCING THE CHICAGO MPN ROUNDTABLE

August 2013 Incyte Corp. has announced two new trials that are currently recruiting ET and PV patients: Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study According to representatives from Incyte,… Read More »NEW TRIAL RECRUITING PV AND ET PATIENTS

In 2010, The U.S. House of representatives declared September to be a time in which to raise awareness and support activities that will help people living with all types of blood cancer. In September the MPN community will have a unique opportunity to draw attention to polycythemia vera, essential thrombocythemia and myelofibrosis by celebrating national Blood… Read More »Take action this September to change your prognosis

September 3, 2013 by Andrew Schafer, MD, Scientific Advisory Board Chair and Chairman of Medicine, Weil Cornell Since 2000, the MPN Research Foundation has provided nearly $9 million in research funding to advance the treatment of the myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera and myelofibrosis.) It is a modest amount relative to the magnitude of… Read More »MPN BCAM 2013: PATIENTS IN ACTION

October 26, 2013 On Thursday October 24, 2013, the MPNRF met with Representatives and Senators from around the country to deliver a message: stop sequestration now and restore funding to cancer research. While organizations like MPNRF work hard to fund research independent of the government, the funds raised from individual donors can only go so… Read More »MPNRF GOES TO WASHINGTON

November 7, 2013   The MPN Research Foundation has released a video on the impact PV, ET, and MF patients have had in driving MPN research forward.

Don’t save the date. Instead, join us from the comfort of your own home on #GivingTuesday, December 3rd, 2013. We’re celebrating Giving Tuesday this year by giving you the night off. We are NOT holding a gala on December 3rd to help raise money for MPN research. Instead, you’re invited to stay in and support PV, ET, and… Read More »GIVING TUESDAY

By Sam Klepper As a board member of the MPN Research Foundation for more than 10 years, it has been encouraging to see the progression of the scientific community’s understanding of the MPNs and the development of an initial set of targeted therapies. One of the challenges we face as a foundation is determining which… Read More »CALR MUTATION: FOCUS AREA ONE

January 29, 2015 The New England Journal of Medicine has just published a paper co-authored by Claire N. Harrison, D.M., Ruben Mesa, M.D. and Srdan Verstovsek, M.D., Ph.D. among others, describing the outcome of a trial measuring Ruxolitinb in polycythemia vera patients who are intolerant or who do not respond to Hydroxyurea. Patients were randomly… Read More »NEJM REPORTS ON RANDOMIZED TRIAL OF RUXOLITINIB VS PHLEBOTOMY IN HYDROXYUREA-RESISTANT PV